Featured Story | By Nick Paul Taylor AbbVie has helped Oncternal Therapeutics move a step closer to a phase 3 trial by agreeing to supply the Bruton’s tyrosine kinase inhibitor ibrutinib for use in the study. read more |
| |
|---|
|
Top Stories By James Waldron Many companies like to talk big about how hot the startup scene is in Asia, but Merck KGaA is putting its money where its mouth is. The German drugmaker is offering funding of up to $100,000 to startups across the region that can impress it with their vision. read more By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. read more Sponsored by: Lonza AG Advance your AAV-based therapeutics by leveraging Lonza expertise, using the same tools and technologies used for our platform processes. Balance risk and speed, while maintaining high AAV productivity read more By Nick Paul Taylor Needing a win to reverse its fortunes, Bone Therapeutics is rethinking an ongoing phase 2b clinical trial of its tibial fracture cell therapy. The Belgian biotech plans to change a primary endpoint and add an interim analysis as part of statistical revisions that will enable it to reduce the enrollment target by 20%. read more Sponsored by: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Max Bayer Zymeworks is shifting its corporate home base from Canada to tax-friendly Delaware in a bid to reduce costs. The move is expected to be finalized in the fourth quarter. read more By Gareth Macdonald Cancer patients are more likely to take part in clinical trials that use decentralized technologies, according to analysis by U.S. researchers. The survey, conducted by American Cancer Society Cancer Action Network researchers, looked at the impact “decentralization tools”—wearable and self-report systems, online portals, etc.—have on patient participation in drug trials. read more By James Waldron One of the major causes of increased heart failure risk in older men is the loss of the Y chromosome in immature blood cells called hematopoietic cells. Now, researchers have suggested an already approved drug could be the solution. read more By Fraiser Kansteiner A former Novartis sales representative has accused the company and two of her former supervisors of wrongfully firing her after she blew the whistle on a co-worker who allegedly falsified records. read more By Andrea Park Onkos Surgical’s My3D personalized pelvic reconstruction system aims to help surgeons more easily navigate the challenges associated with the procedure, a major surgery that requires implants to be attached to both bone and soft tissue. read more By Robert King Most health insurers have been complying with a new regulation to post a trove of data on their rates, and experts are detailing how they plan to use it. read more By Teresa Carey This week on "The Top Line," we discuss a potential Merck acquisition of Seagen and how it could be the largest biopharma deal since 2020. Also under discussion is our special report ranking the highest paid biopharma CEOs of the year. Plus, COVID test-to-treat sites, the Biotech Sisterhood and more. read more By Max Bayer,Gabrielle Masson Agios makes a CEO change months after nabbing another FDA approval. Altos Labs snatches Vir's chief scientific officer as the executive team takes shape around Hal Barron. Two top Emerald Health execs resign following SEC fraud probe. read more By Angus Liu BeiGene and Novartis' PD-1 inhibitor was delayed at the FDA. Big Pharma's off-patent drugs once again lost major supply contracts in China's latest price-cutting scheme. A Pfizer partner on a PD-L1 inhibitor in China is reportedly exploring a sale. And more. read more Resources Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Lumanity Check out our 22 on-demand panels, featuring 100+ speakers. Tap into discussions of scientific progress in oncology around development, regulatory, clinical, commercial and investment perspectives. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Decentralized Clinical Trials Forum July 26, 2022 | Free Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Health Payer Forum October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Free Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual Fierce Clinical Trial Billing & Research Compliance Summit February 2023 | Location TBD Fierce BD&L Summit for Life Sciences March 14-15, 2023 | San Francisco, CA | 
